Oaktree Acquisition III Life Sciences reported no operating revenue for the period, recording only interest income from its trust; net income was $7.29 million driven by $8.48 million of interest income offset by approximately $1.20 million of general and administrative expenses. The company has not commenced operations and therefore has no gross profit or operating revenues to report. Results reflect formation, IPO activity and trust investment returns rather than ongoing operating performance.
Financial Highlights
- Revenue: $0, company had no operating revenues to date; interest income only (non‑operating).
- Gross Profit: $0, no operations or sales reported during the periods presented.
- Operating Income: Approximately -$1.20 million, reflecting general and administrative expenses of $1,195,687.
- Net Income: $7.29 million for the year ended Dec 31, 2025, driven by $8.48 million of interest income on trust offset by G&A expenses.
- Net Income Per Share: Not presented in the provided sections.
Business Highlights
- Capital Raise & Trust Funding: Completed an IPO and private placements placing approximately $192 million in trust to finance target business combination activities.
- Operational Focus: The company has not generated operating revenues and is focused on formation activities, IPO-related processes, target identification and due diligence for a business combination.
- Expense Runway & Trust Withdrawals: Incurs public-company and deal-related costs; limited annual permitted withdrawals of trust interest are used to fund working capital.
- Timeline & Going Concern Risk: Must complete a business combination by October 25, 2026 (or seek a shareholder-approved extension); failure to do so may result in liquidation.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.